NASDAQ:BBNX • US08659B1026
The current stock price of BBNX is 13.94 USD. In the past month the price decreased by -21.64%. In the past year, price decreased by -36.08%.
ChartMill assigns a fundamental rating of 4 / 10 to BBNX. While BBNX has a great health rating, there are worries on its profitability.
Over the last trailing twelve months BBNX reported a non-GAAP Earnings per Share(EPS) of -4.37. The EPS decreased by -24.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.59% | ||
| ROE | -26.41% | ||
| Debt/Equity | 0 |
16 analysts have analysed BBNX and the average price target is 29.95 USD. This implies a price increase of 114.86% is expected in the next year compared to the current price of 13.94.
For the next year, analysts expect an EPS growth of 7.15% and a revenue growth 51.43% for BBNX
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.62 | 193.832B | ||
| ISRG | INTUITIVE SURGICAL INC | 47.53 | 169.664B | ||
| SYK | STRYKER CORP | 24.21 | 139.908B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.34 | 109.921B | ||
| BDX | BECTON DICKINSON AND CO | 11.16 | 50.66B | ||
| IDXX | IDEXX LABORATORIES INC | 42.48 | 49.283B | ||
| EW | EDWARDS LIFESCIENCES CORP | 25.52 | 44.358B | ||
| RMD | RESMED INC | 20.57 | 35.869B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16 | 35.845B | ||
| DXCM | DEXCOM INC | 27.73 | 25.383B |
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Beta Bionics, Inc. is a commercial-stage medical device company. The company is headquartered in Irvine, California and currently employs 404 full-time employees. The company went IPO on 2025-01-30. The firm's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The firm's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The firm is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. The company is also in the early stages of developing a bihormonal configuration of the iLet.
BETA BIONICS INC
11 Hughes
Irvine CALIFORNIA US
Employees: 404
Phone: 18002462677
Beta Bionics, Inc. is a commercial-stage medical device company. The company is headquartered in Irvine, California and currently employs 404 full-time employees. The company went IPO on 2025-01-30. The firm's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The firm's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The firm is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. The company is also in the early stages of developing a bihormonal configuration of the iLet.
The current stock price of BBNX is 13.94 USD. The price increased by 2.88% in the last trading session.
BBNX does not pay a dividend.
BBNX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
16 analysts have analysed BBNX and the average price target is 29.95 USD. This implies a price increase of 114.86% is expected in the next year compared to the current price of 13.94.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BBNX.